Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group (Q70909831)
Jump to navigation
Jump to search
scientific article published on 01 January 1996
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group |
scientific article published on 01 January 1996 |
Statements
Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group (English)
W A Knaus
F E Harrell
J F LaBrecque
D P Wagner
J P Pribble
E A Draper
C J Fisher
1 January 1996